LFA-REAL System to Improve Health and Quality of Life
Currently, there are no adequate measures or tools designed to quickly and easily help a doctor and patient work together to evaluate lupus disease activity and make informed treatment decisions. This has serious implications for the care of people with lupus; moreover, the changing face of healthcare delivery makes the situation even more complex. The LFA-REAL™ (Rapid Evaluation of Activity in Lupus) system is being developed as a first-of-its-kind set of tools to monitor lupus disease activity, addressing both the needs and concerns of clinicians and people with lupus.
What is LFA-REAL?
For more information, see LFA, Inc.'s information about LFA-REAL.
UNVEIL understanding the Impact of lupus
Do you have lupus? Do you care for someone with the disease?
Participating in research studies like the UNVEIL survey is crucial to helping us learn more about lupus and discovering new way to mange the disease.
We need more research. We need more treatments. We need a cure. Shre your experiences today. You will be compensated for your time.
Help Us Solve The Cruel Mystery™! Visit lupus.org/unveil for more information.
For more information on EMBODY
The EMBODY program is a global clinical research program testing the safety and effectiveness of an investigational study drug called epratuzumab in people with moderate to severe lupus. As part of the EMBODY program, two clinical research studies are being conducted at over 300 participating study sites in approximately 30 countries worldwide. Approximately 780 people are expected to participate in each study.